Jakob Lindberg, Oncopeptides CSO

On­copep­tides says Swedish au­thor­i­ties end­ed probe in­to CSO Jakob Lind­berg over al­leged in­sid­er in­for­ma­tion shar­ing

Al­most three months af­ter Swedish au­thor­i­ties first ar­rest­ed On­copep­tides chief sci­en­tif­ic of­fi­cer Jakob Lind­berg, they’ve closed their in­ves­ti­ga­tion, the biotech says.

Lind­berg, who for­mer­ly served as CEO of On­copep­tides, came un­der in­ves­ti­ga­tion for al­leged­ly pass­ing in­sid­er in­for­ma­tion to an in­di­vid­ual out­side the com­pa­ny in Oc­to­ber 2021.

But ac­cord­ing to a press re­lease from On­copep­tides, the Swedish Eco­nom­ic Crime Au­thor­i­ty has now de­cid­ed “there is no longer a rea­son to com­plete the pre­lim­i­nary in­ves­ti­ga­tion as ‘the in­ves­tiga­tive ma­te­r­i­al avail­able [does not] prove that the per­son or per­sons who were sus­pect­ed have com­mit­ted any crime.’”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.